Prominent cell and gene therapy vendors in 2023

[Image courtesy of catalin/Adobe Stock]

In recent years, the cell and gene therapy market has grown at a rapid clip. The momentum is likely to continue. According to Vision Research Reports, the global cell and gene therapy market size could hit around $42.56 billion by 2030, growing at a CAGR of 39% from 2022 to 2030.

The burgeoning demand in the industry, along with an increasing number of FDA-approved therapies, is also fueling the growth of cell and gene therapy vendors offering tools and services for product development and manufacturing.

The following table includes notable vendors and suppliers active in the call and gene therapy marketplace. This curated selection of companies includes a brief overview of their focus areas.

We have a separate feature focused on companies with prominent cell and gene therapy development efforts.

Company Name Description Notable partnerships Founded He…
Read more
  • 0

GenScript debuts single- and double-strand DNA service for cell and gene therapy development

The popularity of CRISPR-based non-viral gene insertion techniques is fueling interest in CRISPR/Cas genome-editing technology that uses the homology-directed repair (HDR) pathway to insert DNA sequences.

To respond to that demand, biotech services firm GenScript has introduced GMP-compliant single-stranded DNA (ssDNA) and closed-end linear double-stranded DNA (dsDNA) services.

The company’s GenExact ssDNA services support up to 5000 nt in length and 100mg per batch production scale.  GenWand services offer closed-end, linear dsDNA up to 10,000 nt in length and gram level/batch production scale.

Launching the services at the American Society of Gene & Cell Therapy annual meeting, Piscataway, New Jersey-based GenScript now boasts a range of non-viral HDR payload materials for early discovery research, process development and clinical trials.

The company said the offerings would also help facilitate CAR-T drug development.

“Th…

Read more
  • 0